Your Catalyst to a Lucrative Business
Rapid-acting, long-acting and premix analogs are the three major types of insulin analogs administered
to the patients. These insulin types when delivered duplicate the action of natural insulin and avoid the
excess release of glucose in blood cells. The market penetration of long-acting insulin products is
higher as compared to other two types, however, during the forecast period, the uptake and
acceptance of rapid and premix analogs are anticipated to increase. The reason being the quick action
and optimum performance of these two over long-acting insulin.
The insulin analogs market is consolidated in nature as three companies account for more than 50% of
the total market share. The reason being extensive product offerings and continuous research and
development activities. This market is witnessing an ongoing patent erosion affecting the market
sustainability of companies. Also, high probability of launch of several biosimilars by new entrants,
major players might face competition during the forecast period.
To enhance the overall sustainability, established players such as Novo Nordisk, Sanofi, and Eli Lilly
are continuously investing in the development of the improved versions of insulin products. For
instance, recent launches by Novo Nordisk (Xultophy, Tresiba) and Sanofi's Toujeo (improved version
of Lantus). These factors exhibit the promising growth for type 1 diabetes treatment market.
Hexa Research has segmented the global type 1 diabetes (T1D) market based on insulin analog, and
region:
Segmentation by insulin analog, 2014 - 2024 (USD Million)
• Rapid acting
• Long acting
• Premix analogs
Segmentation by region, 2014 - 2024 (USD Million)
• North America
• U.S.
• Europe
• UK
• Asia Pacific
• China
• India
• Rest of the world
Key players analyzed
• ADOCIA
• Biocon
• Bioton
• Eli Lilly and Company
Follow Us: